Lipopolysaccharide promotes adhesion and invasion of hepatoma cell lines HepG2 and HepG2.2.15.
Inflammation and infection have been linked to the bionomics of many cancers, including hepatocellular carcinoma (HCC). Some bacteria, such as Helicobacter pylori, have been found in pathological specimens from patients with HCC. However, little is known about the direct effects of bacteria or their components on hepatoma cells. We analyzed the in vitro proliferation, adhesion and invasion responses of the tumor cell lines HepG2 and HepG2.2.15 to lipopolysaccharide (LPS), a cell wall constituent of Gram-negative bacteria. HepG2 and HepG2.2.15 cells show increased proliferation in response to LPS. Their invasion and adhesion abilities were also increased in response to LPS, which may be related to increased gene expression of interleukin-8 and transforming growth factor-beta1. We infer that bacteria may be ignored by immune systems and directly promote adhesion and invasion of hepatoma cells through LPS.
Liu
Xudong
X
Department of Liver Disease, Ruikang Hospital of Guangxi Traditional Chinese Medical University, 10 Huadong Road, 530011 Nanning, China. lxdlhx@163.com
Liang
Jian
J
Li
Gang
G
D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000473:pathology*; D002448:Cell Adhesion / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D056945:Hep G2 Cells; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000235:genetics / Q000473:pathology*; D009361:Neoplasm Invasiveness; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism
D016207:Cytokines; D008070:Lipopolysaccharides; D012333:RNA, Messenger
J Clin Invest. 2004 Aug;114(4):569-81
15314694
Radiology. 2000 Sep;216(3):698-703
10966697
Clin Cancer Res. 2000 Jun;6(6):2573-81
10873114
Exp Mol Med. 2002 Dec 31;34(6):462-8
12526088
J Immunol. 2000 Dec 1;165(11):6024-8
11086033
Immunity. 2005 Sep;23(3):319-29
16169504
Cancer Res. 2006 Apr 1;66(7):3859-68
16585214
Nat Immunol. 2004 Oct;5(10):987-95
15454922
J Surg Res. 2001 May 1;97(1):14-9
11319874
J Allergy Clin Immunol. 2006 May;117(5):979-87; quiz 988
16675322
J Neuroendocrinol. 2005 Mar;17(3):152-60
15796767
J Immunol. 2004 Jul 15;173(2):1166-70
15240706
Cancer Detect Prev. 2003;27(6):494-7
14642558
Nat Rev Cancer. 2004 Jan;4(1):71-8
14708027
Mol Immunol. 2007 Apr;44(11):2850-9
17328955
Liver. 2002 Oct;22(5):394-403
12390475
Cancer Cell. 2007 Oct;12(4):300-1
17936555
Int J Cancer. 2002 Oct 10;101(5):415-22
12216068
J Clin Pathol. 2004 Dec;57(12):1273-7
15563667
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4140-9
15217951
Br J Cancer. 1999 Dec;81(8):1311-7
10604727
Ann N Y Acad Sci. 2004 Jun;1019:330-2
15247038
J Immunol. 2003 Jan 15;170(2):795-804
12517943
Int J Mol Med. 2004 Feb;13(2):221-7
14719127
Toxicol Lett. 2007 Jun 15;171(1-2):78-86
17543481
World J Gastroenterol. 2004 Feb 15;10(4):598-601
14966925
Haematologica. 2004 Apr;89(4):391-402
15075072
Cancer Lett. 2006 Apr 8;235(1):75-83
15922507
Clin Invest Med. 2008;31(3):E123-30
18544275
Nature. 2002 Dec 19-26;420(6917):860-7
12490959
Clin Diagn Lab Immunol. 2003 Jul;10(4):558-63
12853386
Eur J Biochem. 1999 Feb;260(1):183-91
10091598
Int J Mol Med. 2004 May;13(5):717-20
15067376